Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Lower-Initiating Dose of Bosutinib for Resistant or Intolerant to Prior Therapy Chronic Myeloid Leukemia Patients (BOGI trial): A Single-Arm, Multicenter, Phase II Trial

Hiroshi Ureshino, Naoto Takahashi, Takayuki Ikezoe, Ayako Takamori, Atsushi Kawaguchi, Tatsuo Ichinohe, Shinya Kimura

Blood (2023) 142 (Supplement 1): 3179.

https://doi.org/10.1182/blood-2023-174594

Published: 2023

Journal Articles

The Outcomes of Pregnancies in Japanese Patients with CML in the TKI Era; A Result of Nationwide Survey

Takeshi Kondo, Eri Matsuki, Tomoiku Takaku, Masaya Okada, Kazunori Murai, Chikashi Yoshida, Naoki Watanabe, Naoto Takahashi, Shinya Kimura, Itaru Matsumura

Blood (2023) 142 (Supplement 1): 1802.

https://doi.org/10.1182/blood-2023-174169

Published: 2023

Journal Articles

In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia

Ho-Jae Han, Eun-Ju Park, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W. Deininger, Jong-Won Kim, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 6336.

https://doi.org/10.1182/blood-2023-185440

Published: 2023

Journal Articles

PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia

Kotoko Yamatani, Tatsuro Watanabe, Kaori Saito, Abhishek Maiti, Satoshi Yamashita, Abdullah Khasawneh, Faith Jessica Paran, Kala Hayes, Gautam Borthakur, Joe R Harman, Shinya Kimura, Courtney D. DiNardo, Thomas A Milne, Michael Andreeff, Yoko Tabe, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4162.

https://doi.org/10.1182/blood-2023-178554

Published: 2023

Journal Articles

Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib

Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W. Deininger, Jong-Won Kim, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 6337.

https://doi.org/10.1182/blood-2023-188135

Published: 2023

Journal Articles

An Open-Label, Multicenter, Single-Arm, Phase I Dose Escalation Study of OP-2100, an Orally Bioavailable Prodrug of Decitabine, for Patients with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Shinya Kimura, Kensuke Usuki, Tatsuo Ichinohe, Takayuki Ikezoe, Junya Kuroda, Senji Kasahara, Sho Okamoto, Hiromitsu Iizuka, Hiroshi Ureshino, Tatsuro Watanabe, Tokihiro Ro, Kosuke Endo, Yuka Kagawa, Yuki Kurahashi, Toshiki Naito, Takahiro Yamauchi

Blood (2023) 142 (Supplement 1): 6466.

https://doi.org/10.1182/blood-2023-173174

Published: 2023

Journal Articles

Mutational Analysis of DNMT3A Improves the Prognostic Stratification Using NPM1 / FLT3 -ITD Genotypes in Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 8914–8916.

https://doi.org/10.1182/blood-2022-158686

Published: 2022

Journal Articles

Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis

Bryan Valcarcel, Haruhiko Sano, Hiroo Katsuya, Atae Utsunomiya, Maki Otsuka, Masaharu Miyahara, Yasushi Takamatsu, Kenji Ishitsuka, Shinya Kimura, Junji Suzumiya, Kazuo Tamura, Daniel J Enriquez, Denisse Castro, Brady E Beltran, Henry Idrobo, Camila Peña, Lorena Fiad, Juan Carlos Ramos, Luis Enrique Malpica Castillo

Blood (2022) 140 (Supplement 1): 6664–6665.

https://doi.org/10.1182/blood-2022-168101

Published: 2022

Journal Articles

Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions

Blood (2022) 140 (Supplement 1): 1072–1073.

https://doi.org/10.1182/blood-2022-168334

Published: 2022

Journal Articles

Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Kotoko Yamatani, Abhishek Maiti, Tatsuro Watanabe, Kaori Saito, Kala Hayes, Sonoko Kinjo, Kazuho Ikeo, Takashi Miida, Shinya Kimura, Courtney D. DiNardo, Xiaoping Su, Yoko Tabe, Marina Konopleva

Blood (2022) 140 (Supplement 1): 3097–3098.

https://doi.org/10.1182/blood-2022-156999

Published: 2022

Journal Articles

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Blood (2021) 138 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2021-149483

Published: 2021

Journal Articles

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Blood (2021) 138 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2021-145483

Published: 2021

Journal Articles

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

Tatsuro Watanabe, Satoshi Yamashita, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Nao Yoshida, Naoko Hattori, Hideaki Nakamura, Akemi Sato, Atsushi Kawaguchi, Naoko Sueoka-Aragane, Kensuke Kojima, Seiji Okada, Toshikazu Ushijima, Shinya Kimura, Eisaburo Sueoka

Blood (2020) 136 (7): 871–884.

https://doi.org/10.1182/blood.2019003084

Published: 2020

Includes: Supplemental data

Journal Articles

The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease

Hidekazu Itamura, MD PhD, Hiroyuki Muranushi, MD, Takero Shindo, MD PhD, Kazutaka Kitaura, DVM, PhD, Seiji Okada, MD PhD, Tadasu Shin-I, PhD, Ryuji Suzuki, DVM, PhD, Akifumi Takaori-Kondo, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 1929.

https://doi.org/10.1182/blood-2019-128913

Published: 2019

Journal Articles

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Kazuharu Kamachi, MD, Hiroshi Ureshino, MD, Nao Yoshida, MD, Yuki Kurahashi, Tatsuro Watanabe, PhD, Seiji Okada, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 5365.

https://doi.org/10.1182/blood-2019-125460

Published: 2019

Journal Articles

The Presence and Possible Role of Virus-Host Chimeric Transcripts in Adult T-Cell Leukemia-Lymphoma

Hiroo Katsuya, MD, Paola Miyazato, PhD, Saiful Islam, Benjy Jek Yang Tan, MD, Yuki Inada, Misaki Matsuo, Takaharu Ueno, Masahito Tokunaga, MD PhD, Hiroyuki Hata, MD PhD, Makoto Yamagishi, PhD, Jun-Ichi Fujisawa, Toshiki Watanabe, MD, PhD, Kaoru Uchimaru, MD, PhD, Atae Utsunomiya, MD, Shinya Kimura, MD PhD, Yorifumi Satou, MD PhD

Blood (2019) 134 (Supplement_1): 2779.

https://doi.org/10.1182/blood-2019-124361

Published: 2019

Journal Articles

Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma

Tatsuro Watanabe, PhD, Hiroshi Ureshino, MD, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Satoshi Yamashita, PhD, Toshikazu Ushijima, MD PhD, Seiji Okada, MD PhD, Eisaburo Sueoka, MD PhD, Shinya Kimura, MD PhD

Blood (2018) 132 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2018-99-117536

Published: 2018

Journal Articles

Downregulation of BMI-1 By the Small Molecule PTC596 Induces Mitochondrial Apoptosis in Mantle Cell Lymphoma

Kensuke Kojima, MD PhD, Aya Maeda, Sho Okamoto, MD, Yuki Nishida, Cao Liangl, Marla Weetall, PhD, Art Branstrom, PhD, Shinya Kimura, MD, PhD

Blood (2017) 130 (Supplement 1): 1263.

https://doi.org/10.1182/blood.V130.Suppl_1.1263.1263

Published: 2017

Journal Articles

Preclinical Anti-Lymphoma Activity of the BCL-2 BH4 Domain Antagonist Bda-366 in Mantle Cell Lymphoma

Sho Okamoto, MD, Aya Maeda, Shinya Kimura, MD, PhD, Kensuke Kojima, MD PhD

Blood (2017) 130 (Supplement 1): 3847.

https://doi.org/10.1182/blood.V130.Suppl_1.3847.3847

Published: 2017

Journal Articles

Automatic Digital Quantification of Bone Marrow Myeloma Volume in Appendicular Skeletons — Clinical Implications and Prognostic Significance

Yuki Nishida, Shinya Kimura, MD, PhD, Hideaki Mizobe, Junta Yamamichi, Kensuke Kojima, MD PhD, Atsushi Kawaguchi, PhD, Manabu Fujisawa, MD, Kosei Matsue, MD PhD

Blood (2017) 130 (Supplement 1): 4401.

https://doi.org/10.1182/blood.V130.Suppl_1.4401.4401

Published: 2017

NARROW

Lower-Initiating Dose of Bosutinib for Resistant or Intolerant to Prior Therapy Chronic Myeloid Leukemia Patients (BOGI trial): A Single-Arm, Multicenter, Phase II Trial

The Outcomes of Pregnancies in Japanese Patients with CML in the TKI Era; A Result of Nationwide Survey

In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia

PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia

Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib

An Open-Label, Multicenter, Single-Arm, Phase I Dose Escalation Study of OP-2100, an Orally Bioavailable Prodrug of Decitabine, for Patients with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Mutational Analysis of DNMT3A Improves the Prognostic Stratification Using NPM1 / FLT3 -ITD Genotypes in Patients with Acute Myeloid Leukemia

Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis

Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions

Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

The Presence and Possible Role of Virus-Host Chimeric Transcripts in Adult T-Cell Leukemia-Lymphoma

Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma

Downregulation of BMI-1 By the Small Molecule PTC596 Induces Mitochondrial Apoptosis in Mantle Cell Lymphoma

Preclinical Anti-Lymphoma Activity of the BCL-2 BH4 Domain Antagonist Bda-366 in Mantle Cell Lymphoma

Automatic Digital Quantification of Bone Marrow Myeloma Volume in Appendicular Skeletons — Clinical Implications and Prognostic Significance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only